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The p53 protein was identified in 1979 through its interaction
with viral oncoproteins (Lane and Crawford, 1979), and has
subsequently been shown to play a central role in cell cycle
control. The TP53 gene is activated in response to DNA damage,
resulting in the elimination of damaged cells by cell cycle arrest
or apoptosis (reviewed in Wahl et al, 1997). The tumour
suppressor gene TP53 maps to chromosome 17p13.1, and is the
most frequently altered gene in human cancer (Hollstein et al,
1991; Levine et al, 1991).
Li-Fraumeni syndrome (LFS) is an inherited cancer disorder,
characterized by a broad but specific range of tumours, with
germline mutations in TP53 detected in approximately 70% of
families (Li et al, 1988; Varley et al, 1997). Fibroblasts derived
from LFS families have therefore been used to examine the mech-
anisms of tumorigenesis. Studies of fibroblasts heterozygous for
germline TP53 mutations have shown that loss of the wild-type
allele, or loss of heterozygosity (LOH), occurs during passaging
(or at increasing population doublings) and is associated with
genomic instability, such as chromosomal aberrations and aneu-
ploidy, and extension of proliferative lifespan (Rogan et al, 1995;
Tainsky et al, 1995; Boyle et al, 1998).
Following on from our previous work looking at the genomic
instability of LFS fibroblast strains at a chromosomal level, we
have analysed changes at a molecular level. In particular we have
studied chromosomal aberrations by Comparative Genomic
Hybridization (CGH), and analysed microsatellite instability and
somatic mutations in TP53.
CGH is a molecular cytogenetic technique which allows
analysis of the entire genome for detection of chromosomal
regions of DNA loss or gain. The technique is based on in situ
hybridization and involves the differential labelling and co-
hybridization of test (tumour or cell line) and reference (normal)
DNAs to normal metaphase chromosomes. Developed in 1992 as a
tool for cancer research (Kallioniemi et al, 1992), the technique
has subsequently been refined to allow detection of regions of gain
of 2 megabases, dependent on copy number increase, and regions
of loss in the order of 10 megabases (Piper et al, 1995; Bentz et al,
1998).
We have used CGH to analyse mutation-carrying fibroblast cell
strains derived from Li-Fraumeni families previously shown to
undergo genomic instability during passaging (Boyle et al, 1998).
In addition, we have analysed cell strains obtained from normal
individuals, at increasing population doublings (PD).
MATERIALS AND METHODS
Both LFS (Li et al, 1988) and LFL (Birch et al, 1994) cell strains
have been classified using the general term Li-Fraumeni (LF,
Boyle et al, 1998).
Cell culture
All cell strains were established, expanded to senescence and
TP53 status characterized, as described previously (Boyle et al,
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doi: 10.1054/ bjoc.2000.1292, available online at http://www.idealibrary.com on 1998). Briefly, skin biopsies were obtained from LF family
members and normal individuals, and used to set up fibroblast cell
cultures. Cell cultures were expanded until senescence by repeated
sub-culture, with cumulative PD calculated from cell counts. At
intervals, aliquots from each cell strain were frozen down. Strain
163MA was separately cultured twice, producing the strains desig-
nated as 163MA-a and 163MA-b. High molecular weight DNA
was extracted from cell aliquots using standard procedures.
Comparative Genomic Hybridization
Cell strains were analysed by CGH, based on the method for high
molecular weight DNA described recently (James, 1999), with
minor modifications. Test (DNA from cell strains) and reference
(normal male DNA; Sigma) DNAs were labelled with
Rhodamine-dUTP (FluoroRed, Amersham) and FITC-dUTP
(Spectrum Green, Vysis Ltd, Richmond, UK) respectively.
Labelling was performed by nick translation to an optimum size of
200–3000 bp, with test and reference DNAs size-matched for each
sample. Labelled DNAs (1 mg of each) and 50 mg Cot-1 DNA
were combined, ethanol precipitated, and re-suspended in 10 ml of
Hybridization Buffer (50% deionized formamide in 23 SSC/10%
dextran sulphate). This probe mixture was denatured at 80°C for 8
minutes and pre-annealed for 30 minutes at 37°C, before applying
to a target slide. Slides were prepared from PHA-stimulated,
synchronized peripheral blood lymphocytes from a normal male
donor, and denatured for 3–5 minutes at 72–75°C, depending on
slide batch. Hybridization was carried out under a glass coverslip,
in a moist chamber (50% formamide/23 SSC) at 37°C for 120
hours. Following hybridization, slides were washed to high strin-
gency as described previously, and counterstained with an antifade
solution containing DAPI.
Image acquisition and analysis
Image acquisition and analysis were performed as described previ-
ously (James et al, 1997; James, 1999). Briefly, slides were viewed
under a Zeiss Axioskop Fluorescence Microscope, and grey level
images captured for each fluorochrome using a Photometrics CCD
camera. Images were processed using Vysis Quips Software. At
least 5 metaphases were analysed from each sample.
Each CGH experiment included a control slide with normal
male DNA labelled as both test and reference. This slide was used
to set fluorescence ratio threshold values, generally of 0.88 and
1.12, for analysis of cell strains. Any region exceeding these
values was characterized as a loss or a gain respectively. Regions
exceeding a value of 1.5 were defined as high level amplifications.
Heterochromatic regions and the entire Y chromosome were
excluded from analysis. CGH experiments were repeated on some
samples to ensure reproducibility of results, and hybridization of
normal male DNA vs. female DNA was also included as a control.
Mismatch repair and microsatellite analysis
Two mononucleotide tracts (BAT26 and BAT40, Parsons et al,
1995) and four dinucleotide repeat sequences (D2S123, D3S1076,
D8S255 and D13S175, Dib et al, 1996) were analysed. DNA was
amplified in a 10 ml reaction mix containing reduced unlabelled
dCTP and 1 mCi 32P-dCTP per reaction. All sequences were ampli-
fied for 35 cycles of 94°C, 56°C and 72°C each for 1 minute
following an initial 4 minute denaturation at 94°C. Microsatellites
were analysed by electrophoresis on a 6% denaturing acrylamide
gel, and visualised by autoradiography.
Mutation detection
Exons 5–8 of TP53 were amplified from each sample and the
products were screened initially by SSCP. Included in the analysis
were the intron-exon boundaries. The primers which were used,
together with the PCR conditions, are listed in Varley et al (1999).
The products were separated on 0.5 ´ MDE gels (FMC
Biochemicals) at 4–6 W for 12–16 h, dried and subjected to
autoradiography. Controls (no DNA and normal DNA) were
included on every gel. Any samples showing abnormal band shifts
were re-analysed by repeating both first- and second-round
SSCP–PCR reactions.
Wherever possible, early and late passage cells were analysed
for both somatic mutation to TP53 and microsatellite alterations.
RESULTS
We have analysed three groups of cell strains by CGH: LF muta-
tion-carrying strains which showed LOH for TP53 (five strains),
LF mutation-carrying strains which did not show LOH (three
strains), and strains from normal individuals (five strains). All cell
strains were analysed at regular intervals during expansion of
cultures.
Aberrations detected by CGH, microsatellite changes and
somatic mutations in TP53 are summarized in Table 1, with TP53
mutation and status indicated for each cell strain. Normal cell
strains have not been tested for TP53 mutations due to ethical
constraints, hence TP53 mutation and status are not shown.
Comparative Genomic Hybridization
Four of five LF cell strains with LOH for TP53 (135MA,
160MA, 161MA, 163MA) showed associated loss of several
chromosomal regions, with loss in more than one cell strain
affecting chromosomes 4q (minimal commonly lost region
4q33–35), 6q (6q15–21), 9 (9p; 9qcen–34.1), 16q and 17p
(Figure 1B). The most common chromosomal losses associated
with loss of heterozygosity for TP53 were on the short arm of
chromosomes 9 and 17, both present in at least three cell strains.
Two independent sub-cultures of 163MA (a and b) both showed
specific loss of 3q at late PD, in addition to the commonly
affected regions of loss, with 163MA-b also showing additional
changes, indicated in Table 1 and Figure 1A. Other cell strains in
this group also showed specific regions of loss, such as
11p12–15 in 160MA and 8q in 161MA. Of the five strains
analysed showing loss of heterozygosity for TP53, only one
strain (21MA) did not show any associated chromosomal aberra-
tions, detected by CGH. Only one region of gain was found in all
the cell lines analysed, a high level amplification of 17q in strain
163MA-b at PD43.
LF mutation-carrying strains without LOH for TP53 showed no
chromosomal changes during passaging, when analysed by CGH.
Similarly, none of the five normal strains showed any regions of
loss or gain at any PD, when analysed by CGH. Loss of the TP53
wild-type allele is associated with extension of cellular lifespan
but does not generally result in more rapid growth.
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All samples were analysed for microsatellite instability using a panel
of six microsatellites. Only one sample showed an alteration (Table
1). At late passage 21MA showed loss of one allele of D3S1076. No
sample showed any evidence of microsatellite instability.
All strains from patients with germline TP53 mutations were
analysed for additional somatic mutations and loss of the wild-type
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Table 1 Somatic mutation, microsatellite, and CGH analysis of normal and LF strains.
Straina Family PDb TP53 TP53 somatic Microsatellite CGH analysis
(mutation)a statusc mutationsd instabilitye
Losses Gainsf
Normal controlsg
83MA 7147 3.3 (9) + None None
26.8 (74) + None None
85MA 12.2 (29) + None None
27 (65) None None
41.8 (100) + None None
105MA 13.5 (47) nd None None
21.2 (74) None None
28.6 (100) nd None None
162MA 5575 7.1 (27) nd None None
25.6 (98) nd None None
177MA 2635 11.6 (36) nd None None
25 (79) None None
29.2 (92) nd None None
Li-Fraumeni strains without LOH
110MA 85 (E180K) 13.8 (26) +/mt None None
22.8 (42) +/mt None None
31.8 (59) +/mt None None
40.8 (76) +/mt + nd None None
49.8 (92) +/mt nd + None None
191MA 86 (SA I3) 6.8 (16) +/mt nd + None None
17.4(40) +/mt None None
28.4 (65) +/mt + + None None
194MA 64 (P152L) 7.4 (16) +/mt + + None None
12.8 (28) +/mt None None
36.8 (80) +/mt None None
40.4 (89) +/mt + + None None
Li-Fraumeni strains with LOH
21MA 83 (R175H) 4.1 (9) +/mt – (7) + None None
16.5 (37) +/mt None None
34.4 (78) +/mt -LOH(7) LOH(1/6) None None
36.0 (82) +/mt None None
37.0 (84) –/mt None None
135MA 83 (R175H) 6.3 (8) +/mt + + None None
19.5 (26) +/mt None None
33.7 (45) +/mt None None
48.9 (66) +/mt 4q33–35, 9, 16, 17p None
68.7 (93) –/mt + + 9, 16p, 17p None
160MA 7003 (L344P) 4.4 (26) +/mt nd + 6q13–21 None
13.0 (76) –/mt + + 1q21–41, 9p, 9q21–34.1, None
11p12–15, 17p
161MA 7003 (L344P) 8.0 (42) +/mt nd + 8q21.3–22 None
17.6 (93) –/mt + + 8q, 13, 17p None
163MA-a 266 (R248W) 7.8 (11) +/mt + + None None
25.2 (36) +/mt None None
45.7 (65) +/mt 9p None
65.8 (94) –/mt + + 3q, 9p, 17p None
163MA-b 266 (R248W) 15.4 (36) +/mt nd nd None None
29.2 (68) +/mt 4q34–qter None
43 (100) –/mt + + 3q, 4q32–qter, 6q15–22, 17q
8p, 9p, 9qcen–34.1,
16q, 17p, Xq
aStrain and family numbers are as previously (Varley et al, 1997; Boyle et al, 1998; Boyle et al, 1999). bPD, population doubling. Figure in parenthesis shows the
percentage of the maximum doubling time. cTP53 status: +, wild type allele; – loss of the wild type allele (LOH); mt, mutant allele. dSomatic mutations of TP53
exons 5–8, found by SSCP analysis: nd, not determined; +, normal; –, mutation detected with affected exon indicated in parentheses; LOH, loss of
heterozygosity detected with affected exon indicated in parentheses. eMicrosatellite analysis of 6 loci: nd, not determined; +, normal; –, microsatellite instability
of one or more loci detected, with affected number indicated in parentheses; LOH, loss of heterozygosity of one or more loci detected, with affected number
indicated in parentheses. fAmplifications are indicated by bold typeface. gNormal strains have not been tested for TP53 mutations, therefore TP53 status and
somatic mutations are not shown for this group.allele. This analysis was not carried out on strains from normal
donors for ethical reasons. At early and mid passage strain 21MA
showed an SSCP band-shift in exon 7, with loss of the corre-
sponding normal sequence in the mid passage sample. This is inter-
esting because there was no loss of the wild-type sequence
corresponding to the germline mutation until late passage, indicating
that there is a complex series of genetic alterations at the TP53 locus
in these cells. A similar situation has been reported in childhood
tumours from patients with germline TP53 mutations (Varley et al,
1999). Details of the samples with LOH are given in Table 1.
In cell strains with germline TP53 mutations and no LOH, and
in normal cell strains neither changes to the microsatellites tested
nor somatic mutations to exons 5–8 of TP53 were seen.
DISCUSSION
Previously it has been shown that there is a strong correlation
between loss of the wild-type TP53 allele and chromosome insta-
bility, in cells from LFS families with germline TP53 mutations
(Boyle et al, 1998). It has also been postulated that this instability
is the result of the conversion from a +/mt to a –/mt genotype. We
have therefore analysed five cell strains from normal individuals
and eight cell strains derived from LF families to assess genomic
instability at a molecular level, and to dissect the events
surrounding loss of the wild-type TP53 allele. Amongst the LF cell
strains, we have analysed both LF mutation-carrying strains with
and without loss of heterozygosity for TP53, to deduce whether
instability is the result of genotype conversion or a property of
mutation-carrying strains irrespective of loss of the wild-type
allele, as proposed by Tainsky et al (1995).
Using CGH, we have found loss of several distinct chromo-
somal regions associated with loss of the wild-type TP53 allele in
LF mutation-carrying strains, summarized in Table 1 and Figure
1B. In cell strains with LOH the most recurrent changes were loss
of chromosomes 9p and 17p. It is likely that the targets for deletion
in these regions could be genes involved in the control of cell
proliferation and whose loss would confer a selective growth
advantage on cells, such as tumour suppressor genes.
Chromosome 17p contains the TP53 gene and 9p harbours the p16
tumour suppressor gene, on chromosome band 9p21. The p16
gene (also known as CDKN2, MTS1 and INK4), is inactivated in a
variety of primary tumours and tumour cell lines (Kamb et al,
1994; Cairns et al, 1995). In addition an alternatively spliced tran-
script, encoding p19ARF, is derived from the same locus as p16, and
is therefore co-deleted in a number of malignancies (Mao et al,
1995; Quelle et al, 1995; Stone et al, 1995).
Interestingly, other work on LFS fibroblasts in culture has iden-
tified loss of both p16 and p53 function involved in the extension
of proliferative lifespan and immortalization (Rogan et al, 1995;
Noble et al, 1996). Whilst we have not detected immortalization in
our set of LF strains, an increase in longevity (or proliferative
lifespan) has been noted in these mutation-carrying strains
compared to the control group (Boyle et al, 1998).
Other recurrent regions of loss have been detected by CGH, in
particular loss of chromosomes 4q33–35, in cell strains 135MA
and 163MA-b, and 6q15–21, in cell strains 160MA and 163MA-b
(Figure 1). Microcell fusion studies have identified chromosomes
containing senescence related genes, including chromosomes 4
and 6q (recently reviewed in Reddel, 1998). Inactivation of these
regions has also been documented in several types of cancer, indi-
cating the presence of one or more tumour suppressor genes. A
potential tumour suppressor gene, MORF 4, has been identified in
the region 4q33–34 (Bertram et al, 1999), although this has been
excluded as the keratinocyte senescence gene (Bryce et al, 1999).
A novel p53 target gene, PA26, has recently been characterized
and localised to 6q21 (Velasco-Miguel et al, 1999), a region
containing an unknown gene capable of inducing senescence
(Morelli et al, 1997).
Whilst we have detected several regions of loss associated with
LOH for TP53 we have only found one associated region of gain,
an amplification of the long arm of chromosome 17 in cell strain
163MA-b (shown in Figure 1). Gene amplification of 17q has been
reported in a number of cancers, including breast and ovarian
cancer (reviewed in Knuutila et al, 1998), and commonly involves
the oncogene ERBB2 at 17q21. Amplification of 17q22–24 is also
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Figure 1 Comparison of common DNA regions of imbalance detected by
CGH in cell strains with LOH. The figure shows chromosomes 4, 6, 9, 16,
and 17. (A) Cell strain 163MA-b at i) PD29 (before LOH) and ii) PD43 (after
LOH), with fluorescence ratio profiles and corresponding CGH images of
chromosomes shown. Hybridization is of Rhodamine-labelled test DNA and
FITC-labelled reference DNA on to DAPI stained normal chromosomes.
Chromosomal regions of loss appear green and regions of gain appear red
on representative CGH images. On ratio profiles, red and green vertical lines
correspond to threshold values of 0.88 (loss) and 1.12 (gain) respectively.
The number of chromosome homologues (n) used to calculate the ratio is
indicated below each profile. Chromosome ideograms are shown alongside
the ratio profiles. Blue and red bars on the left side of each chromosome
ideogram represent DNA losses before and after LOH respectively, whilst
green bars on the right side represent gains after LOH (no gains were
detected before LOH). Double-thickness green bars represent high level
amplifications. (B) Summary of changes detected in two or more cell strains.
The ideograms of each chromosome are shown, with coloured bars (blue,
red or green) representing regions of DNA loss or gain as above. Specific
cell strain numbers are indicated above each bara frequent event in breast cancer, and the gene PS6K has recently
been localized to this region (Couch et al, 1999).
As well as detecting a number of recurrent chromosomal
changes by CGH, we have also detected a number of strain
specific changes, exemplified by the two independent sub-cultures
of 163MA. Whilst both 163MA-a and 163MA-b showed loss of
chromosomes 9p and 17p, seen in other cell strains with LOH,
both sub-cultures also had loss of chromosome 3q at late PD, not
seen in other strains. In addition, sub-culture 163MA-b also
showed additional changes associated with LOH that 163MA-a
did not exhibit (shown in Figure 1).
Overall, of the five mutation-carrying strains with LOH, only
21MA did not have any detectable chromosomal changes using
CGH. This strain also did not show increased chromosomal aber-
rations associated with LOH, unlike other mutation-carrying
strains (Boyle et al, 1998). However this was the only strain within
the group that demonstrated changes at both a microsatellite locus
and a somatic TP53 mutation. Therefore 21MA appears to be atyp-
ical in having no chromosomal aberrations or CGH changes, but
nonetheless does have genetic alterations.
None of the mutation-carrying strains without LOH for TP53
had detectable chromosomal changes. These results support the
model of genomic instability as a function of genotypic conversion
rather than a property of mutation-carrying strains. However,
using CGH we detected chromosomal changes prior to LOH for
TP53 in all the mutation-carrying strains with LOH. This result
could be due to the sensitivity of LOH analysis, where the pres-
ence of a small proportion of +/mt cells against a background of
–/mt cells can give a TP53 status of +/mt. We also detected loss of
chromosomal regions prior to LOH which could not be detected
following LOH, confirmed by experimental repetition. One
possible explanation could be that the first chromosomal change
may become redundant on the appearance of subsequent changes,
and may therefore be lost. Of the five control strains analysed by
CGH at increasing PD, none showed any chromosomal changes,
as expected.
In summary, we have shown that loss of distinct chromosomal
regions is associated with LOH in LF cell strains, and involves
regions containing genes involved in cell cycle control or senes-
cence. It is likely that these changes are a function of genotypic
conversion.
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